medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2019, Number 5

<< Back Next >>

Rev Invest Clin 2019; 71 (5)

Quality of Health Care and Viral Suppression Among Human Immunodeficiency Virus Patients

Luna-Mireles Y, Doubova SV, Pérez-Cuevas R

Language: English
References: 50
Page: 330-338
PDF size: 88.43 Kb.


ABSTRACT

Background: In Mexico, the quality of health care for human immunodeficiency virus (HIV) patients is unknown. The study objectives were to develop quality of care (QoC) indicators for outpatient care of HIV patients, evaluate the quality of the processes of care (QPC) and outcomes, and analyze the association between the QPC and viral suppression among HIV patients. Methods: The study used a mixed-methods approach: Development of QoC indicators through RAND/UCLA method; cross-sectional study of QoC evaluation; and multiple Poisson regressions to measure the association between the QPC and viral suppression. The study included 439 HIV patients, ≥ 19 years of age, with at least one outpatient consultation during 2017 at a public hospital in the State of Mexico. Results: We developed 21 QoC indicators to evaluate HIV care. Based on these indicators, the QoC gaps that emerged were related to clinical history (24% of patient records included sexual history information), routine adherence assessment (no records demonstrated regular recording of antiretroviral treatment adherence), and screening and referral (50% were screened for depression, and 42% for tuberculosis; 1.2% of patients with abnormal body mass index were referred to a dietitian). On average, HIV patients received 63% of recommended QPC; 77.7% achieved viral suppression. Receiving over 75% of recommended QPC was associated with a higher probability of viral suppression (adjusted prevalence ratio 1.13, 95% confidence interval 1.03-1.24). Conclusions: Evaluation of the QoC for HIV patients is essential to identify and address gaps in health-care quality to increase the probability of viral suppression.


REFERENCES

  1. World Health Organization. HIV/AIDS. Key facts: 19 July 2018. Available from: http://www.who.int/news-room/fact-sheets/ detail/hiv-aids.

  2. Remien RH, Rabkin JG. Psychological aspects of living with HIV disease: a primary care perspective. West J Med. 2001;175:332-5.

  3. Mangili A, Murman DH, Zampini AM, Wanke CA. Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort. Clin Infect Dis. 2006;42:836-42.

  4. Crabtree-Ramirez B, Del Rio C, Grinsztejn B, Sierra-Madero J. HIV and noncommunicable diseases (NCDs) in Latin America: a call for an integrated and comprehensive response. J Acquir Immune Defic Syndr. 2014;67 Suppl 1:S96-8.

  5. Cardona-Arias JA, Higuita-Gutierrez LF. Impact of HIV/AIDS on quality of life: meta-analysis 2002-2012. Rev Esp Salud Publica. 2014;88:87-101.

  6. Kruk ME, Gage AD, Arsenault C, Jordan K, Leslie HH, Roder- DeWan S, et al. High-quality health systems in the sustainable development goals era: time for a revolution. Lancet Glob Health. 2018;6:e1196-252.

  7. Ahonkhai AA, Bassett IV, Ferris TG, Freedberg KA. Improving HIV outcomes in resource-limited countries: the importance of quality indicators. BMC Health Serv Res. 2012;12:427.

  8. Engelhard EA, Smit C, Nieuwkerk PT, Reiss P, Kroon FP, Brinkman K, et al. Structure and quality of outpatient care for people living with an HIV infection. AIDS Care. 2016;28:1062-72.

  9. Catumbela E, Certal V, Freitas A, Costa C, Sarmento A, da Costa Pereira A, et al. Definition of a core set of quality indicators for the assessment of HIV/AIDS clinical care: a systematic review. BMC Health Serv Res. 2013;13:236.

  10. Cescon AM, Cooper C, Chan K, Palmer AK, Klein MB, Machouf N, et al. Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site canadian cohort. HIV Med. 2011;12:352-60.

  11. Joao EC, Gouvea MI, Menezes JA, Sidi LC, Cruz ML, Berardo PT, et al. Factors associated with viral load suppression in HIV-infected pregnant women in Rio de Janeiro, Brazil. Int J STD AIDS. 2012;23:44-7.

  12. O’Connor J, Smith C, Lampe FC, Johnson MA, Chadwick DR, Nelson M, et al. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV. 2017;4:e295-302.

  13. Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, august 2014-july 2015. BMC Infect Dis. 2017;17:326.

  14. GBD 2015 HIV Collaborators. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980- 2015: the global burden of disease study 2015. Lancet HIV. 2016;3:e361-87.

  15. Secretaria de Salud. Centro Nacional para la Prevencion y el Control del VIH y el SIDA (Censida). Epidemiological Surveillance of HIV/AIDS Cases in Mexico National Registry of AIDS Cases. Mexico: secretaria de Salud; 2017.

  16. Gutierrez C, Lavadenz F, Macias C, Petravic J, Lavadenz L. Health, Nutrition and Population (HNP) Discussion Paper. Optimizing Investments in the National HIV Response of Mexico. Washington DC: the International Bank for Reconstruction and Development/ The World Bank; 2018.

  17. Secretaria de Salud. Centro Nacional para la Prevencion y el Control del VIH y el Sida (Censida). National Report on Progress in the Response to HIV and AIDS. Mexico: secretaria de Salud; 2016.

  18. Campbell SM, Braspenning J, Hutchinson A, Marshall MN. Research methods used in developing and applying quality indicators in primary care. BMJ 2003;326:816-9.

  19. Secretaria de Salud. Antiretroviral Treatment of the Adult Patient with HIV Infection. Clinical Practice Guideline. Mexico: Gobierno Federal; 2017.

  20. Secretaria de Salud. Centro Nacional para la Prevencion y el Control del VIH y el SIDA (Censida). Guideline for Antiretroviral Management of People with HIV. Novena Edicion. Mexico: censida/ Secretaria de Salud; 2018.

  21. U.S. Department of Health and Human Services. Health Resources and Services Administration, Guide for HIV/AIDS Clinical Care. Rockville, MD: U.S. Department of Health and Human Services; 2014.

  22. DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services; 2017.

  23. Churchill D, Waters L, Ahmed N, Angus B, Boffito M, Bower M, et al. British HIV association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Med. 2016;17 Suppl 4:s2-104.

  24. European AIDS Clinical Society. Guidelines. Version 9. EACS; 2017. Available from: http://www.eacsociety.org/files/guidelines_9.0- english.pdf.

  25. WHO Guidelines Approved by the Guidelines Review Committee. Consolidated Guidelines on the use of Antiretroviral Drugs for Treating and Preventing HIV Infection: recommendations for a Public Health Approach. 2nd ed. Geneva: world Health Organization; 2016.

  26. Polo R, Gomez-Candela C, Miralles C, Locutura J, Alvarez J, Barreiro F, et al. Recomendaciones de SPNS/GEM/SENPE/AEDN/ SEDCA/GESIDA Sobre Nutricion en el Paciente con Infeccion por VIH. Espana: ministerio de Sanidad y Consumo; 2006.

  27. UNAIDS. Global AIDS Monitoring 2017. Indicators for Monitoring the 2016 United Nations Political Declaration on Ending AIDS. 2017 GUIDANCE Geneva: UNAIDS; 2017.

  28. PEPFAR. President’s Emergency Plan for AIDS Relief. PEPFAR Monitoring, Evaluation, and Reporting (MER 2.0) Indicator Reference Guide; 2017. Available from: https://www.pepfar.gov/ documents/organization/263233.pdf.

  29. von Wichmann MA, Locutura J, Blanco JR, Riera M, Suarez-Lozano I, Saura RM, et al. GESIDA quality care indicators for the care of persons infected by HIV/AIDS. Enferm Infecc Microbiol Clin. 2010;28 Suppl 5:6-88.

  30. The Global Fund 35th Board Meeting. 2017-2022 Strategic Key Performance Indicator Framework GF/B35/07 A Revision 1. Abidjan: board Decision; 2016.

  31. Valdiserri RO, Forsyth AD, Yakovchenko V, Koh HK. Measuring what matters: development of standard HIV core indicators across the U.S. Department of health and human services. Public Health Rep. 2013;128:354-9.

  32. Shekelle PG, MacLean CH, Morton SC, Wenger NS. Assessing care of vulnerable elders: methods for developing quality indicators. Ann Intern Med. 2001;135:647-52.

  33. McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro A, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348:2635-45.

  34. Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003;3:21.

  35. Passin WF, Kim AS, Hutchinson AB, Crepaz N, Herbst JH, Lyles CM, et al. A systematic review of HIV partner counseling and referral services: client and provider attitudes, preferences, practices, and experiences. Sex Transm Dis. 2006;33:320-8.

  36. Chesney MA. The elusive gold standard. Future perspectives for HIV adherence assessment and intervention. J Acquir Immune Defic Syndr. 2006;43 Suppl 1:S149-55.

  37. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339-47.

  38. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181-3.

  39. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in sub-saharan Africa and North America: a meta-analysis. JAMA. 2006;296:679-90.

  40. Costa JM, Torres TS, Coelho LE, Luz PM. Adherence to antiretroviral therapy for HIV/AIDS in Latin America and the caribbean: systematic review and meta-analysis. J Int AIDS Soc. 2018; 21:e25066.

  41. Duggal S, Chugh TD, Duggal AK. HIV and malnutrition: effects on immune system. Clin Dev Immunol. 2012;2012:784740.

  42. Petersen M, Yiannoutsos CT, Justice A, Egger M. Observational research on NCDs in HIV-positive populations: conceptual and methodological considerations. J Acquir Immune Defic Syndr. 2014;67 Suppl 1:S8-16.

  43. Tang AM, Quick T, Chung M, Wanke CA. Nutrition assessment, counseling, and support interventions to improve health-related outcomes in people living with HIV/AIDS: a systematic review of the literature. J Acquir Immune Defic Syndr. 2015;68 Suppl 3:S340-9.

  44. Nakimuli-Mpungu E, Bass JK, Alexandre P, Mills EJ, Musisi S, Ram M, et al. Depression, alcohol use and adherence to antiretroviral therapy in sub-saharan Africa: a systematic review. AIDS Behav. 2012;16:2101-18.

  45. Lu HF, Hsiao FH, Sheng WH, Liao SC, Wu PY, Yang YL, et al. Prevalence and predictors of depression among people living with HIV/AIDS: a National study. Nurs Res. 2018;67:379-86.

  46. Wolff L C, Alvarado M R, Wolff RM. Depression in HIV infection: prevalence, risk factors and management. Rev Chilena Infectol. 2010;27:65-74.

  47. Feuillet P, Lert F, Tron L, Aubriere C, Spire B, Dray-Spira R, et al. Prevalence of and factors associated with depression among people living with HIV in France. HIV Med. 2017;18:383-94.

  48. World Health Organization. Factsheet on HIV-Associated Tuberculosis. WHO; 2018. Available from: https://www.who.int/tb/ areas-of-work/tb-hiv/tbhiv_factsheet.pdf?ua=1.

  49. Silow-Carroll S, Edwards JN, Rodin D. Using electronic health records to improve quality and efficiency: the experiences of leading hospitals. Issue Brief (Commonw Fund). 2012;17:1-40.

  50. Perez-Cuevas R, Doubova SV, Jasso-Gutierrez L, Flores-Hernandez S, Cuevas GO, Aranza-Doniz C, et al. Evaluation of the quality of care of neonates with necrotizing enterocolitis affiliated with seguro popular in Mexico. Bol Med Hosp Infant Mex. 2014;71:76-82.




2020     |     www.medigraphic.com